S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea flag South Korea · Delayed Price · Currency is KRW
27,600
+1,650 (6.36%)
At close: Oct 10, 2025
6.36%
Market Cap327.33B
Revenue (ttm)17.10B
Net Income (ttm)-8.84B
Shares Out11.86M
EPS (ttm)-754.38
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume130,886
Average Volume102,810
Open26,150
Previous Close25,950
Day's Range25,800 - 27,750
52-Week Range16,130 - 36,200
Beta1.83
RSI73.38
Earnings DateNov 13, 2025

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 304360
Full Company Profile

Financial Performance

In 2024, S.Biomedics's revenue was 13.73 billion, an increase of 4.77% compared to the previous year's 13.11 billion. Losses were -6.69 billion, -35.17% less than in 2023.

Financial Statements

News

There is no news available yet.